South Africa

Primary goal

Reschedule medical psilocybin to Schedule 6 under the Medicines and Related Substances Act so that a single prescription can authorise a course of treatment of up to 30 consecutive days, with dose and regimen set by a medical professional based on patient history, concurrent medicines, indication, weight, age, and clinical risk.

What has been achieved

• Built an evidence-graded public education library (conditions, citations, and labeled anecdotal cases) to support policy conversations with clinical context rather than hype.
• Mapped South Africa’s current legalization/status framing on the PSILORIS legalization map for public education.
• Documented Australia’s TGA Authorised Prescriber model as the primary international reference for a controlled medical pathway.

What is being done now

• Ongoing desk research on SAHPRA scheduling (Schedule 7 today vs Schedule 6 medical-control mechanics).
• Tracking publicly reported constitutional and advocacy activity around psilocybin in South Africa, while separating private-use litigation from a medical scheduling ask.
• Drafting PSILORIS’s South Africa policy position: Schedule 6 medical access with clinician-directed dosing and 30-day prescription limits aligned to existing Medicines Act controls.

What we plan next

• Publish a formal South Africa briefing note for clinicians, patients, and policymakers summarizing evidence grades and the Schedule 6 ask.
• Engage with professional and patient stakeholders once the position paper is ready (PSILORIS has not yet filed or sponsored a legislative amendment).
• Compare Section 21 / unregistered-medicine pathways with a durable Schedule 6 listing, and identify the least-restrictive medical route that still protects public safety.

Current landscape in South Africa

Under the Medicines and Related Substances Act 101 of 1965, medicines are placed in schedules that control who may supply them and under what conditions. SAHPRA’s consolidated schedules list psilocybin/psilocin among the most restrictive categories used for substances not recognised for routine medical supply (commonly discussed as Schedule 7 territory): possession and supply remain tightly constrained outside narrow scientific contexts, and there is no established national prescribing pathway comparable to Australia’s.

Separately from medical scheduling, South Africa has seen high-profile constitutional and advocacy activity seeking relief around private adult use and related rights arguments. Public reporting about the status of that litigation has been mixed and fast-moving; PSILORIS treats those developments as part of the landscape to monitor, not as a completed medical-access regime. Commercial supply, unlicensed facilitation, and any claim of a general “legal therapy market” should not be assumed.

PSILORIS has not yet pushed its own Bill, petition, or SAHPRA rescheduling application. Our present phase is research, documentation, and goal definition so that any future advocacy is evidence-led and specific.

What Schedule 6 means — and why it is our target

South African scheduling is a ladder of control. Broadly: lower schedules allow wider pharmacy or over-the-counter access; higher schedules demand tighter medical supervision. Schedule 5 covers many psychotropic medicines that still require diagnosis and management but can often be repeated for longer courses when the law and the prescription allow. Schedule 6 is the tier for substances with moderate-to-high abuse or dependence potential that still have recognised medical use — the law requires close supervision and strict supply controls. Schedule 7 is reserved for substances not recognised for ordinary medical use, with possession treated as unjustifiable outside limited scientific purposes.

Key Schedule 6 supply rules under section 22A of the Medicines Act (as reflected in SAHPRA scheduling guidance and the Act’s text) include: sale only through authorised channels (typically pharmacist supply on an authorised prescriber’s prescription); a Schedule 6 prescription is not repeatable without a new prescription being issued; and a Schedule 6 substance may only be sold if the course of treatment does not exceed 30 consecutive days. Prescription/order particulars for Schedule 6 are exacting (including quantity expressed in figures and words). Direct-to-public advertising of Schedule 6 substances is prohibited.

That is exactly the control envelope PSILORIS wants for medical psilocybin in South Africa: not recreational retail, and not an open-ended refill model. A single prescription authorising up to 30 days of treatment forces deliberate clinical review before any further course, while still giving clinicians room to individualise dose and session structure inside that window.

Our specific Schedule 6 goal

Goal statement: move medical psilocybin out of a non-medical / ultra-restrictive posture and into Schedule 6 as a prescription medicine, so that registered medical professionals can prescribe patient-specific regimens — including dose, preparation, setting requirements, and monitoring — based on clinical history, medication history (including SSRIs/SNRIs, MAOIs, lithium, benzodiazepines, and other interacting drugs), indication, body weight, age, comorbidities, and risk of adverse effects.

The “single prescription / 30 days” feature is not a loophole; it is the existing Schedule 6 limit. We want to use that existing architecture rather than invent a novel parallel market. In practice, a 30-day course could cover a supervised dosing session plus a defined acute follow-up period under the same prescription, after which a new clinical decision (and new prescription) would be required for any further treatment course.

What we are not asking for in this goal: adult-use commercial sales, unlicensed retreat markets, or advertising-driven demand. PSILORIS’s medical ask is deliberately narrower than private-use litigation narratives, and deliberately more clinician-centred than unregulated access.

Australia as the worldwide legislative reference

Australia is PSILORIS’s primary international reference because it created the first national medical pathway for psilocybin through medicines scheduling rather than through a recreational market. From 1 July 2023, the Therapeutic Goods Administration (TGA) enabled authorised psychiatrists to prescribe psilocybin for treatment-resistant depression (and MDMA for PTSD) under the Authorised Prescriber scheme, with human research ethics committee (HREC) approval and TGA authorisation. Outside those controlled uses, the substances remain far more restricted (Schedule 9 / prohibited-substance logic for other uses).

Important differences to keep honest: Australia’s pathway is indication-limited, psychiatrist-limited, and currently oriented to unapproved/unregistered products supplied under strict protocols — not a general GP open-formulary model. TGA materials also emphasise controlled clinical settings; take-home recreational framing is not the model. PSILORIS does not copy Australia’s exact Schedule 8 label into South African law; we translate the principle — tightly supervised medical prescribing for serious mental-health care — into South Africa’s Schedule 6 machinery, which already encodes non-repeatable prescriptions and a maximum 30-day treatment course.

Why Australia still leads our reference set: it proves a democracy can move psychedelics from “no medical pathway” to “authorised specialist prescribing” without legalising recreational markets, and it forces advocates to talk about ethics review, specialist competence, indication boundaries, and product quality — the same themes a SAHPRA-facing Schedule 6 strategy must address.

Work done, work underway, and next steps

Done so far (PSILORIS): evidence library and public education infrastructure; country status mapping; articulation of the Schedule 6 + 30-day prescription goal; comparative research on Australia’s TGA Authorised Prescriber regime and South African scheduling definitions.

Underway: deeper monitoring of South African legal developments and SAHPRA schedule publications; refining the clinical rationale for individualised dosing under a Schedule 6 prescription; preparing materials that separate medical scheduling from private-use advocacy so policymakers are not handed a confused ask.

Not yet started (explicitly): PSILORIS has not lodged a formal rescheduling application, sponsored a private member’s Bill, or run a parliamentary lobbying campaign. Those steps come after the research brief is solid enough to defend under clinical and legal scrutiny.

Sources

• SAHPRA — Guideline to the Scheduling of Substances and Medicines (SAHPGL-CEM-NS-02)
• SAHPRA — Consolidated Schedules
• Medicines and Related Substances Act 101 of 1965 (scheduling / supply framework)
• SA Health Review — psychotropic medicines and Schedule 5/6 supply rules
• TGA — classification change for psilocybin and MDMA (Australia)
• TGA — MDMA and psilocybine hub